Navigation Links
Drug Inhibits Colon Cancer in Mice
Date:2/12/2009

Treated with enzastaurin, even tumors that did develop weren't as advanced, study finds

THURSDAY, Feb. 12 (HealthDay News) -- A drug called enzastaurin significantly reduced the development of colon cancer in mice, and tumors that did develop were less advanced and aggressive than those in mice that didn't receive the drug, according to a study by researchers at the Mayo Clinic in Florida.

The findings, coupled with the fact that the drug appears to have minimal side effects, suggest that enzastaurin might offer an effective chemopreventive treatment in people at high risk for colon cancer, the researchers said. The study is to be published in the Feb. 15 issue of the journal Cancer Research.

"There is a need for an agent that has a proven ability to reduce colon cancer risk, and this study suggests that enzastaurin could be uniquely effective," senior investigator Nicole Murray, of the department of cancer biology, said in a Mayo news release.

Enzastaurin is designed to suppress signaling through the PKC-beta pathway. In a previous study, the Mayo team found that the pathway is necessary for the start of colon cancer in mice exposed to a carcinogen.

"These mice develop tumors similar to tumors found in humans, but mice without the PKC-beta gene do not," Murray said.

In the new study, the Mayo researchers gave enzastaurin daily to one group of mice and then exposed them, as well as a control group of mice that didn't receive the drug, to a carcinogen that causes colon tumors.

After 22 weeks, 50 percent of the treated mice and 80 percent of the untreated mice had developed tumors. The tumors that did develop in the treated mice were not as advanced as those in the untreated mice.

Enzastaurin is currently being tested to treat a range of human cancers, including B-cell lymphoma and high-grade brain gliomas.

More information

The U.S. National Ca
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Oncogene inhibits tumor suppressor to promote cancer: Study links B-RAF and LKB1
2. Herpes drug inhibits HIV replication, but with a price
3. Grapefruit Compound Inhibits Hepatitis C Virus
4. Calorie restriction inhibits, obesity fuels development of epithelial cancers
5. Calorie restriction limits Calorie restriction inhibits, obesity fuels development of epithelial can
6. Ingredient found in green tea significantly inhibits breast cancer growth in female mice
7. Penn scientists find a protein that inhibits Ebola from reaching out to infect neighboring cells
8. Embryonic Stem Cell Protein Inhibits Melanoma
9. Blocking protein kills prostate cancer cells, inhibits tumor growth, Jefferson scientists find
10. Helicobacter pylori inhibits intercellular communication of cultured gastric cells
11. Rural Areas Able to Increase Colon Cancer Screenings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Inhibits Colon Cancer in Mice
(Date:9/22/2014)... a very familiar "lub-dub" pattern that speeds up or ... pattern itself isn,t as regular as you might think. ... vary even at a "constant" heart rateand that variability, ... Reduced heart rate variability (HRV) has been found to ... congestive heart failure and inflammation. For athletes, a drop ...
(Date:9/22/2014)... 22, 2014 WHO: LiveOps, Inc., ... customer service solutions. , WHAT: The 10th annual ... customer care for the connected consumer. Constant change ... offer new challenges and opportunities for customer experience ... identify best practices, network and learn from fellow ...
(Date:9/22/2014)... By Tara Haelle ... (HealthDay News) -- Measuring how quickly a child,s brain ... according to a new study. Observing children,s ... is currently possible, the study authors reported. "The ... information is associated with autism severity is hugely promising," ...
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... California for a three-day conference to discuss brain-related ... brain injury from concussions and neurodegenerative disorders. ... medical director affiliated with a Silverado memory care ... of dedicated expertise in memory care, hosts the ...
(Date:9/22/2014)... September 22, 2014 The report ... application, end user, and geography. The equipment segment ... physiotherapy equipment market, by product. However, the accessories ... CAGR in the forecast period, owing to the ... Electric stimulation and ultrasound segments are the fastest-growing ...
Breaking Medicine News(10 mins):Health News:Variability keeps the body in balance 2Health News:Variability keeps the body in balance 3Health News:Variability keeps the body in balance 4Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 5
... offers a low cost, non-invasive alternative to conventional ... having coronary artery disease; true even if the ... a study performed at the Thomas Jefferson University ... patients who had one or more calcified coronary ...
... shown that babies exposed to tobacco in utero are ... are at increased risk for sudden infant death syndrome. ... these babies are also less likely to self-soothe and ... did not smoke during pregnancy. , Researchers from The ...
... the leading,provider of internet and digital information accessibility ... award-winning System Access,software. With this release, Serotek ... support for 64-bit operating systems. This is ... IT professionals,alike. , ...
... ROME, N.Y., Dec. 1 To help prevent the spread ... is using two new,products that kill germs on hands and ... According to Infection Prevention Director LeAnna Grace, the hospital,conducted a ... sanitizing lotion to evaluate how well they work and was ...
... is a statement from Jeff Levi, Ph.D., Executive Director of ... and Drug Administration,s (FDA) progress report on the Food Protection ... lacks a real plan for food protection. The staff ... some key initiatives to improve food safety, but they can ...
... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" or ... significantly reduce costs, centralize core operations, and refocus the Company,s ... found significant market acceptance. The restructuring program includes: , ... personnel of eight full-time employees (40% of the workforce) , ...
Cached Medicine News:Health News:Newborns exposed to maternal smoking more irritable, difficult to soothe 2Health News:Serotek First to Offer 64-Bit Support 2Health News:MRSA and C. difficile Infections Reduced by 50% in Hospital Study 2Health News:MRSA and C. difficile Infections Reduced by 50% in Hospital Study 3Health News:TFAH Statement: FDA Food Protection Plan is Insufficient 2Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 2Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 3Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 4Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 5Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 6Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 7
(Date:9/22/2014)... Sept. 22, 2014  AbbVie (NYSE: ... studies evaluating potential new medicines in the company,s ... 2014 European Society of Medical Oncology (ESMO) Annual ... . Data being presented include results from ... efficacy of veliparib (ABT-888), a poly (adenosine diphosphate ...
(Date:9/22/2014)... BRIDGEWATER, N.J. , Sept. 22, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today is pleased to announce that TUV-SUD ... the Netherlands (MEB) has granted its ... catheter lock solution.  Neutrolin was initially approved in ...
(Date:9/22/2014)... NEW YORK , Sept. 22, ... has signed an exclusive, global license agreement with ... commercialization of its proprietary plasma fractionation process. Concurrently, ... and its intention to strategically refocus and rebrand ... plans to pursue a national listing for its ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) today reported ... Cash, cash equivalents, and investments at September 30, ... 31, 2010. Revenue for the third quarter of ... in the third quarter of 2010 primarily as a result of ...
... NEW YORK, Nov. 2, 2011 JDRF and The Leona ... largest non-government funders of type 1 diabetes (T1D) programs, announced ... a new level of cooperation between the organizations. The goal ... and development to deliver better treatments, devices, and diagnostics for ...
Cached Medicine Technology:Nektar Therapeutics Reports Third Quarter 2011 Financial Results 2Nektar Therapeutics Reports Third Quarter 2011 Financial Results 3Nektar Therapeutics Reports Third Quarter 2011 Financial Results 4Nektar Therapeutics Reports Third Quarter 2011 Financial Results 5Nektar Therapeutics Reports Third Quarter 2011 Financial Results 6Nektar Therapeutics Reports Third Quarter 2011 Financial Results 7Nektar Therapeutics Reports Third Quarter 2011 Financial Results 8JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 2JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 3JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 4
... Western Blot Kits provide a sensitive and ... Borrelia burgdorferi. Proteins from the spirochete are ... antigens are fractionated according to molecular weight ... in the presence of sodium dodecyl sulfate. ...
Surgitie&trade Single Use Ligating Loops with Delivery System...
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO STITCH™ Single Use Loading Units....
Medicine Products: